There is a substantial financial burden of type 2 diabetes mellitus (T2DM) not only regionally but globally, that is forecast to keep growing due to increasing prevalence of T2DM and the increasing costs of medical care. Health economic studies are designed to maintain the sustainability of healthcare system, by identifying interventions that are either cost saving or good value for money (i.e. cost-effective). Many diabetes prevention interventions have not only demonstrated efficacy in clinical trials, but have also been identified as being cost-effective or even cost saving.